$838 Million is the total value of Bain Capital Life Sciences Investors, LLC's 33 reported holdings in Q3 2022. The portfolio turnover from Q2 2022 to Q3 2022 was 17.1% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| SWTX | SPRINGWORKS THERAPEUTICS INC | $137,837,000 | +15.9% | 4,831,307 | 0.0% | 16.45% | +17.9% | |
| NUVALENT INC | $66,641,000 | +43.4% | 3,428,014 | 0.0% | 7.96% | +45.9% | ||
| MRSN | MERSANA THERAPEUTICS INC | $58,566,000 | +46.3% | 8,663,673 | 0.0% | 6.99% | +48.9% | |
| ARQT | ARCUTIS BIOTHERAPEUTICS INC | $57,330,000 | -10.3% | 3,000,000 | 0.0% | 6.84% | -8.7% | |
| DVAX | Sell | DYNAVAX TECHNOLOGIES CORP | $56,533,000 | -46.6% | 5,415,000 | -35.7% | 6.75% | -45.7% |
| EQRX INC | $49,518,000 | +5.5% | 10,003,573 | 0.0% | 5.91% | +7.4% | ||
| CRNX | CRINETICS PHARMACEUTICALS IN | $45,281,000 | +5.3% | 2,305,558 | 0.0% | 5.40% | +7.2% | |
| New | THIRD HARMONIC BIO INC | $43,253,000 | – | 2,280,082 | +100.0% | 5.16% | – | |
| Sell | AMYLYX PHARMACEUTICALS INC | $28,803,000 | -23.2% | 1,023,214 | -47.5% | 3.44% | -21.9% | |
| RAPID MICRO BIOSYSTEMS INC | $27,244,000 | -24.9% | 8,434,560 | 0.0% | 3.25% | -23.5% | ||
| CARA | CARA THERAPEUTICS INC | $24,780,000 | +2.5% | 2,647,473 | 0.0% | 2.96% | +4.3% | |
| PHVS | PHARVARIS N V | $24,395,000 | -65.3% | 3,180,601 | 0.0% | 2.91% | -64.7% | |
| NRIX | NURIX THERAPEUTICS INC | $23,752,000 | +2.8% | 1,822,883 | 0.0% | 2.84% | +4.7% | |
| ANNX | Buy | ANNEXON INC | $22,260,000 | +82.1% | 3,601,926 | +11.1% | 2.66% | +85.4% |
| 2SEVENTY BIO INC | $20,500,000 | +10.2% | 1,408,901 | 0.0% | 2.45% | +12.2% | ||
| PTGX | PROTAGONIST THERAPEUTICS INC | $19,057,000 | +6.6% | 2,260,572 | 0.0% | 2.28% | +8.5% | |
| SVRA | SAVARA INC | $18,015,000 | +2.0% | 11,622,598 | 0.0% | 2.15% | +3.8% | |
| CCCC | C4 THERAPEUTICS INC | $14,402,000 | +16.3% | 1,642,210 | 0.0% | 1.72% | +18.4% | |
| AVIR | ATEA PHARMACEUTICALS INC | $14,143,000 | -19.9% | 2,485,638 | 0.0% | 1.69% | -18.5% | |
| XFOR | Buy | X4 PHARMACEUTICALS INC | $10,926,000 | +274.9% | 6,389,436 | +111.6% | 1.30% | +281.3% |
| ACAD | Buy | ACADIA PHARMACEUTICALS INC | $9,988,000 | +18.0% | 610,523 | +1.7% | 1.19% | +20.2% |
| MARINUS PHARMACEUTICALS INC | $9,517,000 | +37.4% | 1,431,058 | 0.0% | 1.14% | +39.9% | ||
| XILIO THERAPEUTICS INC | $8,164,000 | -0.3% | 2,805,413 | 0.0% | 0.98% | +1.5% | ||
| New | SYROS PHARMACEUTICALS INC | $6,971,000 | – | 1,082,404 | +100.0% | 0.83% | – | |
| TANGO THERAPEUTICS INC | $6,957,000 | -20.1% | 1,921,790 | 0.0% | 0.83% | -18.7% | ||
| INVIVYD INC | $6,063,000 | -4.6% | 1,937,207 | 0.0% | 0.72% | -2.8% | ||
| ARYA SCIENCES ACQUISITN CORP | $4,905,000 | +0.9% | 500,000 | 0.0% | 0.58% | +2.6% | ||
| BLSA | BCLS ACQUISITION CORP | $4,885,000 | +1.2% | 487,500 | 0.0% | 0.58% | +3.0% | |
| NAUT | NAUTILUS BIOTECHNOLOGY INC | $4,240,000 | -21.2% | 2,000,000 | 0.0% | 0.51% | -19.8% | |
| SLDB | SOLID BIOSCIENCES INC | $3,700,000 | -24.2% | 7,929,918 | 0.0% | 0.44% | -22.9% | |
| APTX | APTINYX INC | $3,273,000 | -34.0% | 8,891,758 | 0.0% | 0.39% | -32.8% | |
| FLACU | FRAZIER LIFESCIENCES ACQU COunit 12/09/2025 | $3,045,000 | +2.8% | 300,000 | 0.0% | 0.36% | +4.6% | |
| AGLE | AEGLEA BIOTHERAPEUTICS INC | $2,813,000 | +4.1% | 5,347,689 | 0.0% | 0.34% | +6.0% | |
| PANA | Exit | PANACEA ACQUISITION CORP II | $0 | – | -500,000 | -100.0% | -0.57% | – |
| SYRS | Exit | SYROS PHARMACEUTICALS INC | $0 | – | -6,264,420 | -100.0% | -0.71% | – |
| ARYD | Exit | ARYA SCIENCES ACQU CORP IVcl a | $0 | – | -700,000 | -100.0% | -0.80% | – |
| RACB | Exit | RESEARCH ALLIANCE CORP II | $0 | – | -1,000,000 | -100.0% | -1.15% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
- Bain Capital Life Sciences Partners, LP #1
- Bain Capital Life Sciences Fund, L.P. #2
- BC SW, LP #3
- Bain Capital Life Sciences Investors II, LLC #4
- Bain Capital Life Sciences Fund II, L.P. #5
- BCIP Life Sciences Associates, LP #6
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2022-11-14
Signatures
The EDGAR filing(s) were signed by:
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| APTINYX INC | 20 | Q1 2023 | 16.9% |
| SOLID BIOSCIENCES INC | 19 | Q3 2022 | 22.2% |
| SPRINGWORKS THERAPEUTICS INC | 17 | Q3 2023 | 41.8% |
| DICERNA PHARMACEUTICALS INC | 16 | Q3 2021 | 58.6% |
| DYNAVAX TECHNOLOGIES CORP. | 16 | Q3 2023 | 12.4% |
| SAVARA INC | 16 | Q3 2023 | 6.0% |
| X4 PHARMACEUTICALS INC | 16 | Q3 2023 | 3.2% |
| ARCUTIS BIOTHERAPEUTICS, INC. | 15 | Q3 2023 | 20.1% |
| MERSANA THERAPEUTICS, INC. | 14 | Q3 2023 | 8.4% |
| CRINETICS PHARMACEUTICALS, INC. | 14 | Q3 2023 | 5.4% |
View Bain Capital Life Sciences Investors, LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 4 | 2024-02-14 |
| 13F-HR | 2024-02-13 |
| 3 | 2024-02-07 |
| 4 | 2024-01-12 |
| 3 | 2023-12-29 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 3 | 2023-05-30 |
| 4 | 2023-05-30 |
| 13F-HR | 2023-05-15 |
View Bain Capital Life Sciences Investors, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.